Literature DB >> 32696966

High Levels of Psychological Resilience Associated With Less Disease Activity, Better Quality of Life, and Fewer Surgeries in Inflammatory Bowel Disease.

Priya Sehgal1, Ryan C Ungaro2, Carol Foltz3, Brian Iacoviello4, Marla C Dubinsky2, Laurie Keefer2.   

Abstract

BACKGROUND: Stress and depression are risk factors for inflammatory bowel disease (IBD) exacerbations. It is unknown if resilience, or one's ability to recover from adversity, impacts disease course. The aim of this study was to examine the association between resilience and IBD disease activity, quality of life (QoL), and IBD-related surgeries.
METHODS: We performed a cross-sectional study of IBD patients at an academic center. Patients completed the Connor-Davidson Resilience Scale questionnaire, which measures resilience (high resilience score ≥ 35). The primary outcome was IBD disease activity, measured by Mayo score and Harvey-Bradshaw Index (HBI). The QoL and IBD-related surgeries were also assessed. Multivariate linear regression was conducted to assess the association of high resilience with disease activity and QoL.
RESULTS: Our patient sample comprised 92 patients with ulcerative colitis (UC) and 137 patients with Crohn disease (CD). High resilience was noted in 27% of patients with UC and 21.5% of patients with CD. Among patients with UC, those with high resilience had a mean Mayo score of 1.54, and those with low resilience had a mean Mayo score of 4.31, P < 0.001. Among patients with CD, those with high resilience had a mean HBI of 2.31, and those with low resilience had a mean HBI of 3.95, P = 0.035. In multivariable analysis, high resilience was independently associated with lower disease activity in both UC (P < 0.001) and CD (P = 0.037) and with higher QoL (P = 0.016). High resilience was also associated with fewer surgeries (P = 0.001) among patients with CD.
CONCLUSIONS: High resilience was independently associated with lower disease activity and better QoL in patients with IBD and fewer IBD surgeries in patients with CD. These findings suggest that resilience may be a modifiable factor that can risk-stratify patients with IBD prone to poor outcomes.
© 2020 Crohn’s & Colitis Foundation. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Crohn disease; disease activity; quality of life; resilience; ulcerative colitis

Mesh:

Year:  2021        PMID: 32696966      PMCID: PMC8128407          DOI: 10.1093/ibd/izaa196

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  28 in total

Review 1.  The global burden of IBD: from 2015 to 2025.

Authors:  Gilaad G Kaplan
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-09-01       Impact factor: 46.802

2.  A simple index of Crohn's-disease activity.

Authors:  R F Harvey; J M Bradshaw
Journal:  Lancet       Date:  1980-03-08       Impact factor: 79.321

3.  Preliminary evidence supporting a framework of psychological adjustment to inflammatory bowel disease.

Authors:  Jennifer L Kiebles; Bethany Doerfler; Laurie Keefer
Journal:  Inflamm Bowel Dis       Date:  2010-10       Impact factor: 5.325

4.  A brief measure for assessing generalized anxiety disorder: the GAD-7.

Authors:  Robert L Spitzer; Kurt Kroenke; Janet B W Williams; Bernd Löwe
Journal:  Arch Intern Med       Date:  2006-05-22

Review 5.  Refocusing IBD Patient Management: Personalized, Proactive, and Patient-Centered Care.

Authors:  Corey A Siegel
Journal:  Am J Gastroenterol       Date:  2018-10-04       Impact factor: 10.864

Review 6.  Controversies Revisited: A Systematic Review of the Comorbidity of Depression and Anxiety with Inflammatory Bowel Diseases.

Authors:  Antonina Mikocka-Walus; Simon R Knowles; Laurie Keefer; Lesley Graff
Journal:  Inflamm Bowel Dis       Date:  2016-03       Impact factor: 5.325

7.  Neuro-psychopharmacogenetics and Neurological Antecedents of Posttraumatic Stress Disorder: Unlocking the Mysteries of Resilience and Vulnerability.

Authors:  Abdalla Bowirrat; Thomas J H Chen; Kenneth Blum; Margaret Madigan; John A Bailey; Amanda Lih Chuan Chen; B William Downs; Eric R Braverman; Shahien Radi; Roger L Waite; Mallory Kerner; John Giordano; Siohban Morse; Marlene Oscar-Berman; Mark Gold
Journal:  Curr Neuropharmacol       Date:  2010-12       Impact factor: 7.363

8.  Psychosocial facets of resilience: implications for preventing posttrauma psychopathology, treating trauma survivors, and enhancing community resilience.

Authors:  Brian M Iacoviello; Dennis S Charney
Journal:  Eur J Psychotraumatol       Date:  2014-10-01

9.  Assessing the Relationship between Sources of Stress and Symptom Changes among Persons with IBD over Time: A Prospective Study.

Authors:  Matthew T Bernstein; Laura E Targownik; Kathryn A Sexton; Lesley A Graff; Norine Miller; John R Walker
Journal:  Can J Gastroenterol Hepatol       Date:  2016-10-04

10.  Stress resilience and the risk of inflammatory bowel disease: a cohort study of men living in Sweden.

Authors:  Carren Melinder; Ayako Hiyoshi; Katja Fall; Jonas Halfvarson; Scott Montgomery
Journal:  BMJ Open       Date:  2017-01-27       Impact factor: 2.692

View more
  2 in total

1.  High Levels of Psychological Resilience Are Associated With Decreased Anxiety in Inflammatory Bowel Disease.

Authors:  Alicia Philippou; Priya Sehgal; Ryan C Ungaro; Kelly Wang; Emilia Bagiella; Marla C Dubinsky; Laurie Keefer
Journal:  Inflamm Bowel Dis       Date:  2022-06-03       Impact factor: 7.290

2.  A randomized controlled trial of a multicomponent online stress reduction intervention in inflammatory bowel disease.

Authors:  Farhad Peerani; Makayla Watt; Kathleen P Ismond; Reid Whitlock; Lindsy Ambrosio; Naomi Hotte; Nicholas Mitchell; Robert J Bailey; Karen Kroeker; Levinus A Dieleman; Jesse Siffledeen; Allen Lim; Karen Wong; Brendan P Halloran; Daniel C Baumgart; Lorian Taylor; Maitreyi Raman; Karen L Madsen; Puneeta Tandon
Journal:  Therap Adv Gastroenterol       Date:  2022-09-27       Impact factor: 4.802

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.